Johnson & Johnson Expands TREMFYA Approval in Egypt to Include Crohn’s Disease and Ulcerative Colitis

TREMFYA Receives New Approval for Inflammatory Bowel Diseases in Egypt
Johnson & Johnson has announced the launch of a new therapeutic indication for TREMFYA (guselkumab) in Egypt. The approval, granted by the Egyptian Drug Authority (EDA), expands the use of the medicine to include the treatment of Crohn’s Disease (CD) and Ulcerative Colitis (UC).
The new approval adds to TREMFYA’s existing indications and strengthens its role as a treatment option for patients living with immune-mediated inflammatory diseases.
The announcement was made during a press conference attended by healthcare professionals, medical experts, and company representatives.
Growing Focus on Crohn’s Disease and Ulcerative Colitis
Crohn’s Disease and Ulcerative Colitis are chronic inflammatory bowel diseases that are receiving increasing attention worldwide and in Egypt. These conditions often affect people during some of the most productive years of their lives and can have a significant impact on daily activities, education, employment, and overall wellbeing.
Medical experts note that more than half of patients are diagnosed with moderate-to-severe disease. Because these conditions are chronic and unpredictable, many patients face ongoing challenges related to symptom management and long-term health outcomes.
Beyond the physical symptoms, patients often experience emotional, social, and financial burdens that can affect their quality of life.
Experts Highlight the Importance of New Treatment Options
Professor Ezzat Ali, Professor of Gastroenterology and Endoscopy and President of both the Egyptian Society for Inflammatory Bowel Diseases and the Egyptian Society of Gastroenterology and Immunology, described the availability of advanced treatment options as an important development for healthcare in Egypt.
According to Professor Ali, expanding therapeutic choices allows physicians to create more personalized treatment plans that better address individual patient needs. He noted that TREMFYA represents one of the latest scientific advances in the field of immune-mediated and inflammatory diseases and reflects the ongoing global effort to improve care for people living with chronic conditions.
The Human Impact of Inflammatory Bowel Disease
Dr. Mohamed Khorshid, Gastroenterology Consultant and President of the Egyptian Foundation for Gastroenterology and Endoscopy Development, emphasized the significant challenges faced by patients living with Crohn’s Disease and Ulcerative Colitis.
He explained that disease flare-ups often lead to fatigue, weakness, and exhaustion, making it difficult for patients to maintain normal daily activities. These challenges can affect education, work performance, and social interactions.
Dr. Khorshid stressed the need for greater disease awareness, earlier diagnosis, and access to comprehensive patient care programs that support long-term disease management.
Egypt Continues to Strengthen Chronic Disease Care
Professor Khaled Hamdy, Professor of Internal Medicine and Gastroenterology at Ain Shams University and Vice President of the Egyptian Society for Crohn’s Disease and Ulcerative Colitis, highlighted the progress Egypt has made in improving chronic disease management.
He pointed to ongoing investments in healthcare infrastructure, patient care pathways, and treatment accessibility as important steps toward building a more sustainable healthcare system.
According to Professor Hamdy, collaboration among healthcare providers, policymakers, industry partners, and patient organizations remains essential for delivering long-term care solutions that meet the evolving needs of patients.
Johnson & Johnson Highlights the Broader Impact of Disease Management
Ahmed El Houfy, Managing Director of Johnson & Johnson Innovative Medicine for Egypt, Jordan, and Northeast Africa, said that Crohn’s Disease and Ulcerative Colitis should be viewed as more than medical conditions.
He explained that chronic diseases can have direct effects on productivity, workforce participation, and overall societal wellbeing. Effective disease management can help patients remain active in their professional and personal lives while improving overall quality of life.
El Houfy stated that the launch of the new TREMFYA indication reflects Johnson & Johnson’s ongoing commitment to supporting Egypt’s healthcare ecosystem through scientific innovation and patient-focused treatment solutions.
Focus on Awareness, Education, and Patient Support
Dr. Heba Hussein, Medical Director of Johnson & Johnson Innovative Medicine for Egypt, Jordan, and Northeast Africa, emphasized that improving outcomes for patients with Crohn’s Disease and Ulcerative Colitis requires more than simply making treatments available.
She highlighted the importance of building a complete support ecosystem that includes disease awareness initiatives, continuous medical education, and patient-centered care pathways designed to improve long-term outcomes.
Dr. Hussein also noted the value of collaboration between healthcare professionals, scientific communities, and patient advocacy organizations to strengthen treatment practices and improve access to care.
TREMFYA’s Expanding Role in Immune-Mediated Diseases
With the addition of Crohn’s Disease and Ulcerative Colitis to its approved indications in Egypt, TREMFYA continues to expand its role in the management of immune-mediated diseases.
The approval provides healthcare professionals with another treatment option for patients living with inflammatory bowel diseases and supports ongoing efforts to improve diagnosis, treatment pathways, and long-term disease management across Egypt.
The milestone also highlights the growing focus on innovation, collaboration, and patient-centered care as healthcare stakeholders work to address the challenges associated with chronic inflammatory diseases.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!